Health Canada has stopped sales of Adderall XR, a commonly prescribed drug for attention deficit hyperactivity disorder, because of concerns that it could cause sudden death . The agency cited data indicating there have been 20 sudden deaths - many in patients who had serious cardiac abnormalities -- related to Adderall XR and immediate-release formulation Adderall, both of which are approved for sale in the United States. FDA reviewed the same data last year and concluded merely that the drug required additional warnings.
This isn't the first time that Canadian regulators have acted more swiftly and strictly than U.S. regulators. Let's see how this one plays out.
Posted by schwitz at February 14, 2005 11:55 AM